Last updated on February 2019

Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium (PROMIS-2)


Brief description of study

The co-primary objectives of the trial are to investigate the effect of the use of inhaled colistimethate sodium, administered twice daily via the I-neb for 24 months, compared to placebo in subjects with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with P. aeruginosa on:

  • the frequency of pulmonary exacerbations;
  • the number of exacerbation-free days.

Clinical Study Identifier: NCT03460704

Find a site near you

Start Over